NO20054370L - Anvendelse av ATII-antagonist for behandling og forhindring av metabolsk syndrom - Google Patents

Anvendelse av ATII-antagonist for behandling og forhindring av metabolsk syndrom

Info

Publication number
NO20054370L
NO20054370L NO20054370A NO20054370A NO20054370L NO 20054370 L NO20054370 L NO 20054370L NO 20054370 A NO20054370 A NO 20054370A NO 20054370 A NO20054370 A NO 20054370A NO 20054370 L NO20054370 L NO 20054370L
Authority
NO
Norway
Prior art keywords
prevention
treatment
metabolic syndrome
antagonist
atii
Prior art date
Application number
NO20054370A
Other languages
English (en)
Norwegian (no)
Other versions
NO20054370D0 (no
Inventor
Anders Ljunggren
Anders Svensson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20054370D0 publication Critical patent/NO20054370D0/no
Publication of NO20054370L publication Critical patent/NO20054370L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20054370A 2003-04-03 2005-09-21 Anvendelse av ATII-antagonist for behandling og forhindring av metabolsk syndrom NO20054370L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0300988A SE0300988D0 (sv) 2003-04-03 2003-04-03 New use
PCT/SE2004/000505 WO2004087136A1 (en) 2003-04-03 2004-03-31 Use of atii antagonist for the treatment or prevention of metabolic syndrome

Publications (2)

Publication Number Publication Date
NO20054370D0 NO20054370D0 (no) 2005-09-21
NO20054370L true NO20054370L (no) 2005-10-31

Family

ID=20290927

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054370A NO20054370L (no) 2003-04-03 2005-09-21 Anvendelse av ATII-antagonist for behandling og forhindring av metabolsk syndrom

Country Status (15)

Country Link
US (1) US20060194856A1 (https=)
EP (1) EP1613309A1 (https=)
JP (1) JP2006522115A (https=)
KR (1) KR20050114671A (https=)
CN (1) CN1771033A (https=)
AU (1) AU2004226517B2 (https=)
BR (1) BRPI0408979A (https=)
CA (1) CA2520960A1 (https=)
IL (1) IL170706A0 (https=)
MX (1) MXPA05010660A (https=)
NO (1) NO20054370L (https=)
NZ (1) NZ542640A (https=)
SE (1) SE0300988D0 (https=)
WO (1) WO2004087136A1 (https=)
ZA (1) ZA200507945B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008067378A2 (en) * 2006-11-28 2008-06-05 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted phenyltetrazoles
JP2015509969A (ja) * 2012-03-16 2015-04-02 グルソックス・バイオテック・アーベー Nox4阻害活性を示すチオフェン−ベースの化合物および療法におけるその使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5266583A (en) * 1992-09-01 1993-11-30 Merck & Co., Inc. Angitotensin II antagonist
GB9406573D0 (en) * 1994-03-31 1994-05-25 Merck Sharp & Dohme Medicaments
DE4439947A1 (de) * 1994-11-09 1996-05-15 Boehringer Mannheim Gmbh 2,2-Dichloralkancarbonsäuren, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
NZ509260A (en) * 1998-07-10 2003-09-26 Novartis Ag Pharmaceutical composition containing valsartan and a calcium channel blocker
IL152081A0 (en) * 2000-04-12 2003-05-29 Novartis Ag Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists
CA2420055C (en) * 2000-08-25 2010-06-01 Takeda Chemical Industries, Ltd. Fibrinogen-lowering agent
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US20030092736A1 (en) * 2001-05-30 2003-05-15 Cheng Peter T. Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
EP1579872B8 (en) * 2002-12-27 2012-11-07 Takeda Pharmaceutical Company Limited Body weight gain inhibitor

Also Published As

Publication number Publication date
US20060194856A1 (en) 2006-08-31
MXPA05010660A (es) 2005-12-12
IL170706A0 (en) 2009-02-11
NZ542640A (en) 2008-06-30
AU2004226517A1 (en) 2004-10-14
NO20054370D0 (no) 2005-09-21
AU2004226517B2 (en) 2008-01-24
ZA200507945B (en) 2007-04-25
WO2004087136A1 (en) 2004-10-14
CN1771033A (zh) 2006-05-10
KR20050114671A (ko) 2005-12-06
BRPI0408979A (pt) 2006-04-04
CA2520960A1 (en) 2004-10-14
JP2006522115A (ja) 2006-09-28
EP1613309A1 (en) 2006-01-11
SE0300988D0 (sv) 2003-04-03

Similar Documents

Publication Publication Date Title
WO2004100875A3 (en) Benzimidazoles, compositions containing such compounds and methods of use
WO2004069158A3 (en) Substituted pyrazoles, compositions containing such compounds and methods of use
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
ATE368031T1 (de) Neue gamma secretase inhibitoren
NO20072223L (no) Glykogenfosforylaseinhibitor forbindelser med farmsoytiske preparater av disse
NO20070049L (no) Pyrrolotriazinderivater anvendelig for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese
TW200745031A (en) Acyl indoles, compositions containing such compounds and methods of use
NO20092639L (no) 4-fenyl-6-(2,2,2-trifluor-1-fenyletoksy)pynmidinbaserte forbindelser og anvendelser derav
DE60137966D1 (de) Anilinopyrimidin derivate als "jnk pathway inhibitoren", zusammensetzungen und damit verbundene behandlungsmethoden
EP1773330A4 (en) SUBSTITUTED PYRAZOLE, SUCH COMPOUNDS AND COMPOSITIONS AND METHOD OF USE THEREOF
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
NO20080475L (no) Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
NO20053792L (no) Heterocykly-3-sulfonylindazoler som 5-hydroksytryptamin-6 ligander
NO20054404L (no) 5,7-Diaminopyrazolo [4,3-D] Pyrimidiner Anvendelige ved behandling av of Hypertensjon
UA84318C2 (ru) Гетерополициклические соединения и их применение как метаботропических антагонистов рецепторов глутамата, фармацевтическая композиция на их основе
NO20082496L (no) Pyrazinderivater
NO20076515L (no) Hydantoinforbindelser
NO20051503L (no) Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme.
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
NO20054876L (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser
NO20064732L (no) Alfa-aminoamidderivater nyttige i behandlingen av urolige bein-syndromet og additive lidelser
NO20080354L (no) Benzofuranylderivater som 5-HT6-reseptorinhibitorer
DE60321810D1 (de) Neue tricyclische derivate als ltd4 antagonisten
BR0212899A (pt) Compostos orgânicos
ATE412636T1 (de) Piperazinylpyridinderivate als mittel gegen adipositas

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application